Deep diveFinance
Braveheart Investment Group

Braveheart continues to expand portfolio


  • Braveheart signals intention to start paying dividends
  • Braveheart in early-stage talks to sell fund management business
  • Growing prospects seen at investee companies Paraytec, Kirkstall and Gyrometric

Quick facts: Braveheart Investment Group

Price: £0.12

Market: AIM
Market Cap: £3.25 m
This is a pivotal time for Braveheart. Growing prospects at Kirkstall, Paraytec and Gyrometric continue to excite the Board, while the investment portfolio, combined with our substantial cash continues to provide solid underpinning to our balance sheet

Trevor E Brown, chief executive


What Braveheart Investment Group does:

Braveheart Investment Group PLC (LON:BRH) is an AIM-listed firm that provides funding and advisory services to small and medium-sized enterprises (SME).

Formed in 1997 as an investment syndicate, it now specialises in four areas – equity financing, debt financing, advisory services and fund management.

Braveheart invests in businesses through its many funds including the Finance Yorkshire Equity Fund, Strathclyde Innovation Fund and Lachesis Seed Fund.

The group, which floated on the London Stock Exchange in 2007, also invests on behalf of high net worth individuals, family offices, institutional investors and public sector organisations across the UK and Europe.

The company has about £71mln of funds under management with its portfolio spanning a number of sectors including healthcare equipment and services, travel and leisure, technology hardware and equipment, software and computer services, electronic and electrical equipment, and pharmaceuticals and biotechnology. 


What it owns

In a portfolio update on 7 June 2019, Braveheart said it now holds five strategic investments in its portfolio alongside other historical investments.

These included biotechnology firm Kirkstall, UV light detection group Paraytec, propeller and rotating shaft monitoring group Gyrometric Systems, microscope imaging firm PhaseFocus and Sentinel Medical, a spin out of Paraytec developing technology to detect cancer cells in urine.

On 8 July, the company said that it had also acquired a 33% stake in Pharm2Farm Limited (P2F), a plant nutrients firm.


Inflexion points

• Announcing the acquisition of its stake in P2F, Braveheart also said it was in negotiations to increase its holdings to 54% by way of a working capital investment

• In April, the company said it had disposed of its fund management arm Viking for £110,000 upfront with up to £170,500 to follow once a performance fee for an outstanding fund management contract was agreed

• In the first half of the current financial year, Braveheart made a profit before tax of £113,000 on revenue of £509,000, compared with a profit before tax of £191,000 on revenue of £397,000 the year before


Blue Sky

At the first half results, Braveheart said, “the investment portfolio, combined with substantial cash, continues to provide a solid underpinning to our balance sheet, and developments in our fund management business offer a new source of fund management revenue in the next financial year”.

With the shares trading around 10.8p as of 8 July 2019, Braveheart carries a market cap of £2.6mln.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Braveheart Investment Group named herein, including the promotion by the Company of Braveheart Investment Group in any Content on the Site, the...



Posting of annual accounts

2 weeks, 5 days ago

REPLACEMENT: Final Results

3 weeks, 2 days ago

Final Results

3 weeks, 2 days ago

Update to the Market

on 06/07/2019

Holding(s) in Company

on 02/12/2019

Holding(s) in Company

on 01/31/2019

3 min read